Janssen Submits NDA to U.S. FDA for the First Darunavir-Based Single Tablet Regimen for the Treatment of HIV-1

TITUSVILLE, NJ, Sept. 25, 2017 – Janssen Research& Development, LLC today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for darunavir 800mg/cobicistat 150mg/emtricitabine...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news